Octreotid Hameln (Octreotide Acetate)

Octreotide acetate, the active ingredient in Octreotid Hameln, is a somatostatin analog presented as an injectable solution for intravenous and subcutaneous use. It is employed to control hormone‑related disorders such as acromegaly, carcinoid syndrome, VIP‑producing tumors, and severe diarrhea linked to neuroendocrine cancers.

GNH USA supplies Octreotid Hameln as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Octreotide acetate acts on neuroendocrine hormone pathways to manage several endocrine and tumor‑related conditions. - Acromegaly: reduces excess growth hormone secretion and associated tissue overgrowth. - Carcinoid syndrome: diminishes flushing and diarrhea by inhibiting serotonin release. - VIP tumors: controls watery diarrhea and electrolyte loss caused by vasoactive intestinal peptide. - Severe diarrhea associated with neuroendocrine tumors: lessens stool volume and frequency.

Octreotide acetate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Abdominal pain: cramping or discomfort. - Diarrhea: increased bowel movements. - Injection site reactions: redness, swelling, or pain. - Hyperglycemia: elevated blood glucose levels. - Gallstones: formation of biliary sludge.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas. - Severe allergic reactions: anaphylaxis, rash, or angioedema. - Cardiac arrhythmias: irregular heart rhythms. - Severe hypoglycemia: dangerously low blood sugar, especially in diabetic patients.

Before initiating therapy with Octreotid Hameln, consider the following safety measures. - Blood glucose monitoring: adjust diabetic therapy as needed. - Gallbladder assessment: evaluate for gallstones or biliary disease. - Renal and hepatic function: dose may require modification in impairment. - Hypersensitivity: discontinue if allergic reactions occur. - Pregnancy and lactation: safety unknown; use only if benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreotide acetate can influence the activity of several concomitant medications.

Major Interactions (Avoid): - Cyclosporine: increased risk of nephrotoxicity. - Oral contraceptives: reduced efficacy, consider alternative contraception. - Quinidine: elevated quinidine plasma levels, risk of toxicity.

Moderate Interactions (Monitor Closely): - Insulin or oral hypoglycemics: may require dose adjustments due to altered glucose control. - Growth hormone therapy: antagonistic effect reducing therapeutic benefit. - Diagnostic imaging agents (e.g., 111In‑pentetreotide): potential interference with imaging results.